PeptidePedia The community reference

Contributions of Peptide_Pete

User contributions·57 logged edits·page 1 of 1

Contributions by Peptide_Pete, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 31,882 edits includes activity predating the current log.

  1. 12:36, 14 Jul 2026 (diff | hist) Cold-chain freight 4,758 ±0 give the closure integrity test by name
  2. 17:56, 19 Jun 2026 (diff | hist) Drug master file 4,325 ±0 add the telehealth prescribing point as attributed
  3. 13:45, 28 May 2026 (diff | hist) Talk:Trifluoroacetate counterion 748 +163 /* Assay interference claim */ reply
  4. 11:42, 2 May 2026 (diff | hist) Talk:Incretin effect 611 +239 /* Percentage calculation — should the formula be explained further? */ reply
  5. 09:28, 18 Apr 2026 (diff | hist) Batch number 4,573 ±0 expand §Assignment
  6. 16:34, 3 Apr 2026 (diff | hist) Qingdao Sigma Chemical 15,455 ±0 rm the price; supplier articles carry no price per PP:VN
  7. 16:48, 22 Mar 2026 (diff | hist) Talk:GLP-1 receptor agonist 885 +226 /* Scope: how much research-chemical material belongs here? */ reply
  8. 06:32, 20 Mar 2026 (diff | hist) Guangzhou JEEP Biotechnology 15,452 ±0 m typo
  9. 13:40, 19 Mar 2026 (diff | hist) Talk:Glucose-dependent insulinotropic polypeptide 748 +164 /* Adipose-tissue mechanism remains speculative */ reply
  10. 17:55, 15 Mar 2026 (diff | hist) Batch number 4,573 ±0 rm the ranking language; this wiki publishes no ranking
  11. 22:35, 10 Mar 2026 (diff | hist) Trifluoroacetate counterion 5,116 ±0 expand §Determination
  12. 09:22, 28 Feb 2026 (diff | hist) Talk:Enteroendocrine L cell 674 +252 /* Plasticity section: obesity claim needs updating */ new section
  13. 11:55, 20 Feb 2026 (diff | hist) Talk:Insulin secretion 611 +79 /* Trigger versus amplification framing */ reply
  14. 15:15, 7 Feb 2026 (diff | hist) Patent expiry and biosimilars 4,553 ±0 add the cross-link to the legal-status-by-jurisdiction list
  15. 08:13, 1 Feb 2026 (diff | hist) Melanotan II 4,649 ±0 add the impurity profile typical of solid-phase synthesis of this sequence
  16. 12:00, 29 Jan 2026 (diff | hist) Shanghai ERP Biotechnology 13,018 +798 expand §Ordering and availability
  17. 12:15, 27 Jan 2026 (diff | hist) Talk:Amylin 885 +194 /* Species difference in aggregation */ reply
  18. 08:07, 23 Jan 2026 (diff | hist) Hunan Aslsen Technology 15,492 +220 rm the discount code added by an anonymous editor
  19. 13:09, 14 Jan 2026 (diff | hist) Talk:Lyophilisation 1,022 +374 /* Is the residual-moisture optimum claim sourced adequately? */ reply
  20. 23:46, 20 Dec 2025 (diff | hist) Area percent purity 8,537 ±0 add the repeatability figure with the number of injections
  21. 10:24, 10 Dec 2025 (diff | hist) AmbioPharm 9,826 +229 add the registered legal name exactly as it appears in the registry record
  22. 06:36, 5 Dec 2025 (diff | hist) Placebo-adjusted effect 4,805 ±0 correct the follow-up duration — the source gives weeks, we had months
  23. 12:31, 23 Oct 2025 (diff | hist) Survodutide 5,445 ±0 m add the molecular formula to the infobox
  24. 06:30, 21 Oct 2025 (diff | hist) Amylin receptor agonist 5,245 ±0 add the structural figure and caption it properly
  25. 15:45, 27 Sep 2025 (diff | hist) SURMOUNT trial programme 5,021 +300 m de-orphan
  26. 19:02, 20 Sep 2025 (diff | hist) Syringe dead space 5,919 +1,804 give the worked example to two significant figures throughout
  27. 03:30, 12 Sep 2025 (diff | hist) Baseline laboratory panel 4,429 ±0 close an unbalanced quotation mark
  28. 02:52, 12 Sep 2025 (diff | hist) Research use only 7,724 ±0 add the telehealth prescribing point as attributed
  29. 14:09, 9 Sep 2025 (diff | hist) MOTS-c 4,435 ±0 m state that no human efficacy trial has been published for this peptide
  30. 03:11, 2 Sep 2025 (diff | hist) Glucagon 7,074 ±0 m rm duplicated pharmacokinetics — the same figures appear in the infobox
  31. 17:20, 8 Aug 2025 (diff | hist) Amylin receptor agonist 4,965 ±0 add see also to the amylin analogue
  32. 03:17, 7 Jul 2025 (diff | hist) Haemoglobin A1c 4,096 ±0 expand §Use in this field
  33. 14:52, 22 Jun 2025 (diff | hist) Retatrutide 5,894 ±0 add the year of first marketing authorisation, with the regulator named
  34. 08:36, 11 May 2025 (diff | hist) Melanotan II 3,694 +44 m expand §Documented harms
  35. 11:43, 6 May 2025 (diff | hist) Cost per milligram 3,122 ±0 add the harm-reduction cross-link
  36. 12:23, 2 May 2025 (diff | hist) Shanghai Sigma-Audley New Material Technology 8,895 +602 expand §External links
  37. 09:57, 7 Apr 2025 (diff | hist) Electrospray ionisation 3,512 +34 state the titration endpoint and the reagent factor
  38. 07:07, 15 Mar 2025 (diff | hist) Amylin 4,252 ±0 add the molecular formula to the infobox
  39. 05:15, 11 Mar 2025 (diff | hist) Albumin binding half-life extension 4,872 ±0 state that the receptor is a class B G-protein-coupled receptor
  40. 12:07, 26 Feb 2025 (diff | hist) Janoshik Analytical 4,126 ±0 rm the inference from one report to a supplier
  41. 11:58, 18 Dec 2024 (diff | hist) Haemoglobin A1c 3,218 +608 expand §Confounders
  42. 23:43, 8 Dec 2024 (diff | hist) C-peptide 2,537 ±0 m flag the two remaining uncited intervals
  43. 21:17, 26 Nov 2024 (diff | hist) Sarcopenia 1,173 ±0 add the body-composition measurement method to the comparison
  44. 18:11, 1 Nov 2024 (diff | hist) Cagrilintide 2,406 ±0 m correct the molar mass — source gives the free-base figure, we had the salt
  45. 09:00, 1 Nov 2024 (diff | hist) Contraindications of incretin therapy 1,477 +1,477 N start article; incidence figures to follow
  46. 22:38, 31 Oct 2024 (diff | hist) Purity claim inflation 2,238 ±0 m expand §Mechanisms
  47. 02:17, 25 Oct 2024 (diff | hist) Analytical method validation 2,979 ±0 m add the peptide-content point: area percent alone cannot give a mass
  48. 00:19, 16 Oct 2024 (diff | hist) Third-party testing 4,411 +104 add the cost basis, since it shapes who submits
  49. 01:34, 8 Oct 2024 (diff | hist) Medutest 2,708 ±0 state the method the reporting service uses, since it is not the only one available
  50. 11:26, 4 Oct 2024 (diff | hist) Prescribing information 2,203 +272 m attribute the survey figure to the survey and give its sample size
  51. 01:32, 24 Sep 2024 (diff | hist) Prescribing information 1,931 ±0 m add the year each price figure refers to
  52. 09:00, 17 Sep 2024 (diff | hist) Blind sampling 2,941 +2,941 N start article on the testing subject
  53. 03:21, 15 Sep 2024 (diff | hist) High-performance liquid chromatography 3,326 +147 m add category for method validation
  54. 00:01, 13 Aug 2024 (diff | hist) Gastric emptying 2,270 +884 add the counter-regulatory glucagon point, sourced
  55. 09:00, 12 Aug 2024 (diff | hist) Liraglutide 1,442 +1,442 N create article — compound stub
  56. 13:40, 25 Jul 2024 (diff | hist) Third-party testing 2,441 +535 correct the description of how lot identifiers are assigned
  57. 18:16, 3 Jul 2024 (diff | hist) Glucagon-like peptide-1 3,005 +1,519 give the fasting and postprandial concentrations with the assay named